var data={"title":"Treatment of exogenous endophthalmitis due to Candida species","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment of exogenous endophthalmitis due to Candida species</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/contributors\" class=\"contributor contributor_credentials\">Carol A Kauffman, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/contributors\" class=\"contributor contributor_credentials\">Marlene L Durand, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/contributors\" class=\"contributor contributor_credentials\">Kieren A Marr, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/contributors\" class=\"contributor contributor_credentials\">Jonathan Trobe, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/contributors\" class=\"contributor contributor_credentials\">Anna R Thorner, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 13, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H866067736\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Candida</em> species are a common cause of fungal endophthalmitis. This infection arises in two discrete ways:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The exogenous form follows trauma, eye surgery, or progression of fungal keratitis (corneal infection). Fungi are directly inoculated into the aqueous <span class=\"nowrap\">and/or</span> vitreous.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The endogenous form follows candidemia, with hematogenous seeding of the eye. Fungi usually first seed the highly vascular choroid, then infection typically progresses through the retina into the vitreous. The aqueous is sometimes involved as well. (See <a href=\"topic.htm?path=treatment-of-endogenous-endophthalmitis-due-to-candida-species\" class=\"medical medical_review\">&quot;Treatment of endogenous endophthalmitis due to Candida species&quot;</a>.)</p><p/><p>The treatment of exogenous endophthalmitis caused by <em>Candida</em> species will be reviewed here. The epidemiology, pathogenesis, clinical manifestations, and diagnosis of fungal endophthalmitis are discussed separately. The treatment of endogenous endophthalmitis caused by <em>Candida</em> species and endophthalmitis due to molds are also presented separately. Bacterial endophthalmitis and <em>Fusarium</em> keratitis as well as candidemia and other types of <em>Candida</em> infection are also discussed separately. (See <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-fungal-endophthalmitis\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis&quot;</a> and <a href=\"topic.htm?path=treatment-of-endogenous-endophthalmitis-due-to-candida-species\" class=\"medical medical_review\">&quot;Treatment of endogenous endophthalmitis due to Candida species&quot;</a> and <a href=\"topic.htm?path=treatment-of-endophthalmitis-due-to-molds\" class=\"medical medical_review\">&quot;Treatment of endophthalmitis due to molds&quot;</a> and <a href=\"topic.htm?path=bacterial-endophthalmitis\" class=\"medical medical_review\">&quot;Bacterial endophthalmitis&quot;</a> and <a href=\"topic.htm?path=treatment-of-candidemia-and-invasive-candidiasis-in-adults\" class=\"medical medical_review\">&quot;Treatment of candidemia and invasive candidiasis in adults&quot;</a> and <a href=\"topic.htm?path=overview-of-candida-infections\" class=\"medical medical_review\">&quot;Overview of Candida infections&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-fusarium-infection\" class=\"medical medical_review\">&quot;Treatment and prevention of Fusarium infection&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H866067796\"><span class=\"h1\">DEFINITION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The term &quot;endophthalmitis&quot; refers to infection within the eye involving the vitreous <span class=\"nowrap\">and/or</span> aqueous (<a href=\"image.htm?imageKey=ID%2F57690\" class=\"graphic graphic_figure graphicRef57690 \">figure 1</a>). Exogenous endophthalmitis signifies that the infection was introduced into the eye from the &quot;outside,&quot; either by trauma, eye surgery, or extension of corneal infection (keratitis).</p><p class=\"headingAnchor\" id=\"H866068119\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>No controlled trials of treatment regimens for exogenous <em>Candida</em> endophthalmitis have been performed. The evidence comes from case reports and small observational studies.</p><p>The choice of therapy must take into account the site and stage of infection, the pharmacology of the available antifungal agents, and existing anecdotal clinical experience [<a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/1-3\" class=\"abstract_t\">1-3</a>]. The approach to therapy may involve a combination of the following modalities:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Systemic antifungal therapy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intravitreal <span class=\"nowrap\">and/or</span> intracameral antifungal therapy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Surgical removal of the vitreous (vitrectomy) and any foreign material (eg, artificial intraocular lens [IOL] implant)</p><p/><p>Our recommendations are generally in keeping with the 2016 Infectious Diseases Society of America guidelines for the management of candidiasis [<a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/4\" class=\"abstract_t\">4</a>].</p><p class=\"headingAnchor\" id=\"H1068616348\"><span class=\"h2\">Approach to treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of <em>Candida</em> endophthalmitis varies depending on whether it is of exogenous or endogenous origin and on the degree of vitreous involvement.</p><p class=\"headingAnchor\" id=\"H3297786872\"><span class=\"h3\">Exogenous endophthalmitis with vitritis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with exogenous <em>Candida</em> endophthalmitis with vitritis, we suggest the following treatment course:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Vitrectomy (when the vitreous is heavily involved) <strong>and</strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intravitreal injection of <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> (5 or 10 mcg in 0.1 mL sterile water) or <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> (100 mcg in 0.1 mL sterile water or normal saline) <strong>and</strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For <em>Candida</em> species that are susceptible to <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> and <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, systemic therapy with oral fluconazole (800 mg [12 <span class=\"nowrap\">mg/kg]</span> loading dose, then 400 to 800 mg [6 to 12 <span class=\"nowrap\">mg/kg]</span> orally daily) or voriconazole (400 mg [6 <span class=\"nowrap\">mg/kg]</span> intravenously [IV] every 12 hours for two doses, then 200 to 300 mg [4 <span class=\"nowrap\">mg/kg]</span> IV or orally every 12 hours) can be used. For fluconazole-susceptible isolates, fluconazole is preferred over voriconazole.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most patients infected with a fluconazole-resistant species can be treated with systemic <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, as discussed below:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For <em>C. krusei</em>, which is inherently resistant to <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> and susceptible to <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, voriconazole should be used.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For <em>C. glabrata</em> isolates that are <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> resistant, <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> should be used if the isolate is shown to be susceptible. It is important to note that cross-resistance between fluconazole and voriconazole is common among <em>C. glabrata</em> isolates, and patients infected with this species should be followed carefully for their response to treatment.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In patients who present acutely, the IV formulation of <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> is recommended initially prior to switching to oral therapy. Oral therapy at a dose of 200 to 300 mg orally twice daily can be used following an initial response to the IV formulation.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In patients with a subacute presentation who are being managed as outpatients, the <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> loading dose can be given orally (400 mg [6 <span class=\"nowrap\">mg/kg]</span> twice a day for two doses), followed by an oral maintenance dose of 200 to 300 mg (3 to 4 <span class=\"nowrap\">mg/kg)</span> twice daily.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>It is important to measure serum concentrations of <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> four to seven days after initiating therapy to ensure that adequate concentrations have been achieved to allow success and to avoid high levels that have been associated with adverse events. Although debate remains over the optimal target concentration, available data suggest a therapeutic range between 2 and 5 <span class=\"nowrap\">mg/L</span>. In patients with concentrations that are too high or too low, the serum concentration should be rechecked four to five days after adjusting the dose. (See <a href=\"topic.htm?path=pharmacology-of-azoles#H28\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Voriconazole'</a>.)</p><p/><p>For patients who have an IOL who fail to improve after the therapeutic regimen described above (vitrectomy, intravitreal amphotericin B or <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> injection, and systemic azole therapy), the IOL will likely need to be removed, and repeat intravitreal injections of <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> (5 mcg in 0.1 mL sterile water) or voriconazole (100 mg in 0.1 mL sterile water or normal saline) given.</p><p class=\"headingAnchor\" id=\"H143248736\"><span class=\"h3\">Exogenous endophthalmitis with primarily aqueous involvement</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In cases of exogenous <em>Candida</em> endophthalmitis in which the aqueous is the major site of intraocular infection (eg, from contiguous spread of fungal keratitis), intracameral (into the anterior chamber) injection of <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> (50 mcg in 0.05 mL of sterile water) plus topical voriconazole eyedrops (1%) hourly should be administered. Intracameral <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> (5 mcg in 0.05 mL sterile water) and topical amphotericin B deoxycholate eyedrops (0.15% in sterile water) hourly may be given instead of intracameral voriconazole for voriconazole-resistant strains of <em>Candida</em>. However, amphotericin B deoxycholate eye drops can be very irritating to the eye. Even in cases in which only the aqueous appears to be involved clinically, intravitreal injection of amphotericin B deoxycholate (5 or 10 mcg in 0.1 mL sterile water) or voriconazole (100 mcg in 0.1 mL sterile water or normal saline) should be considered. Such cases may have occult infection of the vitreous.</p><p>In addition to intracameral antifungal therapy, systemic <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> or <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> should be given for susceptible strains, even for cases in which only the aqueous is involved. Dosing is discussed above. (See <a href=\"#H3297786872\" class=\"local\">'Exogenous endophthalmitis with vitritis'</a> above.)</p><p>The management of endogenous endophthalmitis caused by <em>Candida</em> species and endophthalmitis caused by molds are presented separately. (See <a href=\"topic.htm?path=treatment-of-endogenous-endophthalmitis-due-to-candida-species#H6\" class=\"medical medical_review\">&quot;Treatment of endogenous endophthalmitis due to Candida species&quot;, section on 'Treatment'</a> and <a href=\"topic.htm?path=treatment-of-endophthalmitis-due-to-molds#H634314713\" class=\"medical medical_review\">&quot;Treatment of endophthalmitis due to molds&quot;, section on 'Treatment'</a>.)</p><p class=\"headingAnchor\" id=\"H1842267548\"><span class=\"h2\">Duration of therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The duration of antifungal therapy for exogenous <em>Candida</em> endophthalmitis is typically four to six weeks, depending on resolution of lesions as determined by serial ophthalmic examinations [<a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/4,5\" class=\"abstract_t\">4,5</a>].</p><p class=\"headingAnchor\" id=\"H728946907\"><span class=\"h2\">Intraocular therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In cases in which the aqueous is primarily involved (eg, acute <em>Candida</em> endophthalmitis after corneal transplantation), either <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> or <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> may be injected intracamerally (into the anterior chamber) (<a href=\"image.htm?imageKey=ID%2F57690\" class=\"graphic graphic_figure graphicRef57690 \">figure 1</a>). Intracameral injection of amphotericin B deoxycholate has been used for many years for fungal endophthalmitis [<a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/6\" class=\"abstract_t\">6</a>] and appears to be effective [<a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/7,8\" class=\"abstract_t\">7,8</a>]. The usual dose of amphotericin B deoxycholate for intracameral use is 5 mcg in 0.1 mL sterile water. There may be transient increase in eye pain, hypopyon, or intra-aqueous inflammation in some eyes after amphotericin B injection, but this resolves by 24 to 48 hours [<a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/7,8\" class=\"abstract_t\">7,8</a>]. Several studies have reported effective use of intracameral voriconazole at doses ranging from 12.5 mcg to 100 mcg per 0.1 mL [<a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/9-11\" class=\"abstract_t\">9-11</a>]. Intracameral doses of 100 mcg of voriconazole have been used repeatedly in some eyes without any apparent toxicity [<a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/10\" class=\"abstract_t\">10</a>], but we prefer a dose of 50 mcg due to the limited experience with intracameral voriconazole and because this dose produces sufficiently high levels in the aqueous to treat <em>Candida</em> species.</p><p>Once the infection is known to be due to <em>Candida</em> spp, we prefer to use intracameral <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> rather than <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a>, given the potential toxicity of the latter agent. However, in cases in which rapid improvement does not occur with voriconazole, we favor switching to amphotericin B deoxycholate. Efficacy studies comparing intracameral administration of these two agents have not been performed.</p><p>Intracameral <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> has been shown to have a half-life of only 22 minutes in an experimental rabbit model [<a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/12\" class=\"abstract_t\">12</a>], so topical voriconazole 1% solution can be used to prolong the drug level in the aqueous. Application of 1% voriconazole ophthalmic solution (eyedrops) every 2 hours for 24 hours prior to scheduled eye surgery produced high levels in the aqueous in one study of 13 patients [<a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/13\" class=\"abstract_t\">13</a>]. In cases of exogenous <em>Candida</em> endophthalmitis resulting from <em>Candida </em>keratitis, the keratitis should also be treated with antifungal eyedrops. Topical voriconazole eyedrops (1%) are preferred in these cases since topical voriconazole penetrates the cornea and achieves good levels in the aqueous, whereas topical amphotericin B does not.</p><p>It is important to note that intracameral injections of <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> or <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> do <strong>not</strong> produce significant levels in the vitreous, so intravitreal injections of voriconazole or amphotericin B deoxycholate should also be given in any case of exogenous endophthalmitis if vitreous involvement cannot be excluded [<a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/14\" class=\"abstract_t\">14</a>].</p><p>Therapy should include vitrectomy and intravitreal injection of an antifungal agent when the vitreous shows severe involvement. Vitrectomy entails the use of a vitrector, an instrument inserted into the vitreous that simultaneously cuts and aspirates much of the 4 mL of gel-like vitreous into a canister (<a href=\"image.htm?imageKey=ID%2F59512\" class=\"graphic graphic_figure graphicRef59512 \">figure 2</a>). Intravitreal <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> (5 or 10 mcg in 0.1 mL sterile water) has been used most commonly. Since most <em>Candida</em> species are susceptible to <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> and since voriconazole is well tolerated [<a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/15\" class=\"abstract_t\">15</a>], intravitreal voriconazole can be used as an alternative to amphotericin B. The usual dosing for intravitreal voriconazole is 100 mcg in 0.1 mL sterile water or normal saline.</p><p>When infection has resulted from cataract surgery with IOL implantation, it is often necessary to remove the IOL. Antifungal drugs can suppress but cannot always cure the infection without removal of the IOL. This is likely related to the development of a biofilm, which some <em>Candida</em> species readily form on the implant. When antifungal agents are stopped in cases in which the IOL is left in place, relapse is a possibility [<a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/16\" class=\"abstract_t\">16</a>].</p><p>If endophthalmitis has followed corneal transplantation with an infected donor cornea, repeat transplantation, along with intracameral <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> or <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a>, is usually indicated at the onset of endophthalmitis.</p><p class=\"headingAnchor\" id=\"H61418186\"><span class=\"h2\">Systemic antifungal therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to intraocular therapy, we recommend systemic azole therapy, based on the efficacy of systemic azoles in treating endogenous <em>Candida</em> endophthalmitis. (See <a href=\"topic.htm?path=treatment-of-endogenous-endophthalmitis-due-to-candida-species\" class=\"medical medical_review\">&quot;Treatment of endogenous endophthalmitis due to Candida species&quot;</a>.)</p><p>Specific recommendations for systemic antifungal therapy are provided above. (See <a href=\"#H1068616348\" class=\"local\">'Approach to treatment'</a> above.)</p><p><a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">Fluconazole</a> achieves concentrations in the vitreous in humans that are approximately 70 percent of that in the plasma [<a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/17,18\" class=\"abstract_t\">17,18</a>]. Fluconazole has shown efficacy in a rabbit model of exogenous <em>Candida</em> endophthalmitis [<a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/19\" class=\"abstract_t\">19</a>]. <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">Voriconazole</a> has activity against <em>C. krusei</em> and some fluconazole-resistant <em>C. glabrata</em> as well as other common <em>Candida</em> species, and it achieves adequate levels in the eye [<a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/20,21\" class=\"abstract_t\">20,21</a>]. Because <em>C. glabrata</em> isolates can demonstrate cross-resistance to both fluconazole and voriconazole, susceptibility testing should be performed, and the response to therapy should be monitored closely. (See <a href=\"topic.htm?path=treatment-of-candidemia-and-invasive-candidiasis-in-adults#H1393000561\" class=\"medical medical_review\">&quot;Treatment of candidemia and invasive candidiasis in adults&quot;, section on 'C. glabrata and C. krusei'</a>.)</p><p>We generally do <strong>not</strong> recommend systemic amphotericin B for exogenous <em>Candida</em> endophthalmitis because it achieves poor levels in the aqueous and the vitreous [<a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/22\" class=\"abstract_t\">22</a>] and has known systemic toxicities. The value of systemic echinocandins for treating exogenous <em>Candida</em> endophthalmitis is unknown, but it is unlikely that they would be effective because of the poor intraocular concentrations achieved with these agents.</p><p class=\"headingAnchor\" id=\"H148502501\"><span class=\"h1\">OUTCOMES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reports on the outcome of therapy for exogenous <em>Candida</em> endophthalmitis vary from vision restored to normal to light perception only. There are too few cases reported to have a firm idea of outcomes, although one series of 15 patients reported visual acuities of at least <span class=\"nowrap\">20/60</span> in one-half of the patients, most of whom did not have the artificial intraocular lens removed [<a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/23\" class=\"abstract_t\">23</a>].</p><p class=\"headingAnchor\" id=\"H3668652200\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-candidiasis\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Candidiasis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H866068501\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Candida</em> species are a common cause of fungal endophthalmitis, but most cases are endogenous, meaning they develop from hematogenous seeding of the eye during candidemia. Exogenous <em>Candida</em> endophthalmitis, in which <em>Candida</em> is inoculated into the aqueous <span class=\"nowrap\">and/or</span> vitreous from outside the body, is less common (<a href=\"image.htm?imageKey=ID%2F57690\" class=\"graphic graphic_figure graphicRef57690 \">figure 1</a>). Exogenous <em>Candida</em> endophthalmitis occurs most commonly after eye surgery (eg, cataract surgery, corneal transplantation) or penetrating eye trauma but may also occur as an extension of <em>Candida</em> keratitis (corneal infection). (See <a href=\"#H866067736\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with exogenous <em>Candida</em> endophthalmitis require aggressive multimodality therapy to control infection and preserve vision. We use the following approach:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients with exogenous <em>Candida</em> endophthalmitis with vitreous involvement, we recommend vitrectomy for heavy vitritis, along with intravitreal injection of an antifungal agent (<a href=\"grade.htm?i=3\" class=\"grade\">Grade 1C</a>); either <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> (5 or 10 mcg in 0.1 mL sterile water) or <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> (100 mcg in 0.1 mL sterile water or normal saline) may be used. Antifungal injections alone may be considered for light vitreous involvement.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients with exogenous <em>Candida</em> ocular infection with primarily aqueous involvement, we recommend intracameral injection of an antifungal agent (<a href=\"grade.htm?i=3\" class=\"grade\">Grade 1C</a>); either <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> (5 mcg in 0.05 mL sterile water) or <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> (50 mcg in 0.05 mL sterile water or normal saline) may be used. In addition, in patients with exogenous <em>Candida</em> endophthalmitis resulting from <em>Candida</em> keratitis, we also recommend administration of voriconazole eyedrops (1 percent) (<a href=\"grade.htm?i=3\" class=\"grade\">Grade 1C</a>).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For all patients with exogenous <em>Candida</em> endophthalmitis, we recommend systemic azole therapy targeted to the susceptibility of the pathogen (<a href=\"grade.htm?i=3\" class=\"grade\">Grade 1C</a>); many patients can receive <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, but some require <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>All foreign bodies (eg, intraocular lenses placed during prior to cataract surgery) should be surgically removed if primary treatment fails. (See <a href=\"#H1068616348\" class=\"local\">'Approach to treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The management of endogenous endophthalmitis caused by <em>Candida </em>species and endophthalmitis caused by molds is presented separately. (See <a href=\"topic.htm?path=treatment-of-endogenous-endophthalmitis-due-to-candida-species\" class=\"medical medical_review\">&quot;Treatment of endogenous endophthalmitis due to Candida species&quot;</a> and <a href=\"topic.htm?path=treatment-of-endophthalmitis-due-to-molds\" class=\"medical medical_review\">&quot;Treatment of endophthalmitis due to molds&quot;</a>.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/1\" class=\"nounderline abstract_t\">Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis 2011; 52:648.</a></li><li class=\"breakAll\">Durand ML. Endophthalmitis. In: Principles and Practice of Infectious Diseases, 8th, Bennett JE, Dolin R, Blaser MJ (Eds), Churchill Livingstone Elsevier, Philadelphia 2015. Vol 1, p.1415.</li><li class=\"breakAll\">Kauffman CA. Exogenous fungal endophthalmitis. In: Endophthalmitis, Durand ML, Miller JW, Young LH (Eds), Springer International Publishing, Switzerland 2016. p.185.</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/4\" class=\"nounderline abstract_t\">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/5\" class=\"nounderline abstract_t\">Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/6\" class=\"nounderline abstract_t\">Pflugfelder SC, Flynn HW Jr, Zwickey TA, et al. Exogenous fungal endophthalmitis. Ophthalmology 1988; 95:19.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/7\" class=\"nounderline abstract_t\">Kuriakose T, Kothari M, Paul P, et al. Intracameral amphotericin B injection in the management of deep keratomycosis. Cornea 2002; 21:653.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/8\" class=\"nounderline abstract_t\">Yoon KC, Jeong IY, Im SK, et al. Therapeutic effect of intracameral amphotericin B injection in the treatment of fungal keratitis. Cornea 2007; 26:814.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/9\" class=\"nounderline abstract_t\">Wykoff CC, Flynn HW Jr, Miller D, et al. Exogenous fungal endophthalmitis: microbiology and clinical outcomes. Ophthalmology 2008; 115:1501.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/10\" class=\"nounderline abstract_t\">Shen YC, Wang CY, Tsai HY, Lee HN. Intracameral voriconazole injection in the treatment of fungal endophthalmitis resulting from keratitis. Am J Ophthalmol 2010; 149:916.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/11\" class=\"nounderline abstract_t\">Lin RC, Sanduja N, Hariprasad SM. Successful treatment of postoperative fungal endophthalmitis using intravitreal and intracameral voriconazole. J Ocul Pharmacol Ther 2008; 24:245.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/12\" class=\"nounderline abstract_t\">Shen YC, Wang MY, Wang CY, et al. Pharmacokinetics of intracameral voriconazole injection. Antimicrob Agents Chemother 2009; 53:2156.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/13\" class=\"nounderline abstract_t\">Vemulakonda GA, Hariprasad SM, Mieler WF, et al. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch Ophthalmol 2008; 126:18.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/14\" class=\"nounderline abstract_t\">Goyal J, Fernandes M, Shah SG. Intracameral voriconazole injection in the treatment of fungal endophthalmitis resulting from keratitis. Am J Ophthalmol 2010; 150:939; author reply 939.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/15\" class=\"nounderline abstract_t\">Kernt M, Neubauer AS, De Kaspar HM, Kampik A. Intravitreal voriconazole: in vitro safety-profile for fungal endophthalmitis. Retina 2009; 29:362.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/16\" class=\"nounderline abstract_t\">Kauffman CA, Bradley SF, Vine AK. Candida endophthalmitis associated with intraocular lens implantation: efficacy of fluconazole therapy. Mycoses 1993; 36:13.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/17\" class=\"nounderline abstract_t\">Tod M, Lortholary O, Padoin C, Chaine G. Intravenous penetration of fluconazole during endophthalmitis. Clin Microbiol Infect 1997; 3:143.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/18\" class=\"nounderline abstract_t\">Urbak SF, Degn T. Fluconazole in the management of fungal ocular infections. Ophthalmologica 1994; 208:147.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/19\" class=\"nounderline abstract_t\">Park SS, D'Amico DJ, Paton B, Baker AS. Treatment of exogenous Candida endophthalmitis in rabbits with oral fluconazole. Antimicrob Agents Chemother 1995; 39:958.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/20\" class=\"nounderline abstract_t\">Kim JE, Perkins SL, Harris GJ. Voriconazole treatment of fungal scleritis and epibulbar abscess resulting from scleral buckle infection. Arch Ophthalmol 2003; 121:735.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/21\" class=\"nounderline abstract_t\">Breit SM, Hariprasad SM, Mieler WF, et al. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005; 139:135.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/22\" class=\"nounderline abstract_t\">GREEN WR, BENNETT JE, GOOS RD. OCULAR PENETRATION OF AMPHOTERICIN B: A REPORT OF LABORATORY STUDIES AND A CASE REPORT OF POSTSURGICAL CEPHALOSPORIUM ENDOPHTHALMITIS. Arch Ophthalmol 1965; 73:769.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-exogenous-endophthalmitis-due-to-candida-species/abstract/23\" class=\"nounderline abstract_t\">Stern WH, Tamura E, Jacobs RA, et al. Epidemic postsurgical Candida parapsilosis endophthalmitis. Clinical findings and management of 15 consecutive cases. Ophthalmology 1985; 92:1701.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 16220 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H866068501\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H866067736\" id=\"outline-link-H866067736\">INTRODUCTION</a></li><li><a href=\"#H866067796\" id=\"outline-link-H866067796\">DEFINITION</a></li><li><a href=\"#H866068119\" id=\"outline-link-H866068119\">TREATMENT</a><ul><li><a href=\"#H1068616348\" id=\"outline-link-H1068616348\">Approach to treatment</a><ul><li><a href=\"#H3297786872\" id=\"outline-link-H3297786872\">- Exogenous endophthalmitis with vitritis</a></li><li><a href=\"#H143248736\" id=\"outline-link-H143248736\">- Exogenous endophthalmitis with primarily aqueous involvement</a></li></ul></li><li><a href=\"#H1842267548\" id=\"outline-link-H1842267548\">Duration of therapy</a></li><li><a href=\"#H728946907\" id=\"outline-link-H728946907\">Intraocular therapy</a></li><li><a href=\"#H61418186\" id=\"outline-link-H61418186\">Systemic antifungal therapy</a></li></ul></li><li><a href=\"#H148502501\" id=\"outline-link-H148502501\">OUTCOMES</a></li><li><a href=\"#H3668652200\" id=\"outline-link-H3668652200\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H866068501\" id=\"outline-link-H866068501\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/16220|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/57690\" class=\"graphic graphic_figure\">- Eye anatomy in cross section</a></li><li><a href=\"image.htm?imageKey=ID/59512\" class=\"graphic graphic_figure\">- Vitreous aspirate vitrectomy</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=bacterial-endophthalmitis\" class=\"medical medical_review\">Bacterial endophthalmitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-fungal-endophthalmitis\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-candida-infections\" class=\"medical medical_review\">Overview of Candida infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-azoles\" class=\"medical medical_review\">Pharmacology of azoles</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-candidiasis\" class=\"medical medical_society_guidelines\">Society guideline links: Candidiasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-fusarium-infection\" class=\"medical medical_review\">Treatment and prevention of Fusarium infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-candidemia-and-invasive-candidiasis-in-adults\" class=\"medical medical_review\">Treatment of candidemia and invasive candidiasis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-endogenous-endophthalmitis-due-to-candida-species\" class=\"medical medical_review\">Treatment of endogenous endophthalmitis due to Candida species</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-endophthalmitis-due-to-molds\" class=\"medical medical_review\">Treatment of endophthalmitis due to molds</a></li></ul></div></div>","javascript":null}